HazMat Fee +
There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
| Type | HazMat fee for 500 gram (Estimated) |
| Excepted Quantity | USD 0.00 |
| Limited Quantity | USD 15-60 |
| Inaccessible (Haz class 6.1), Domestic | USD 80+ |
| Inaccessible (Haz class 6.1), International | USD 150+ |
| Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
| Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |
Structure of Rebamipide
CAS No.: 90098-04-7
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
Rebamipide is an inducer of endogenous prostaglandin, an oxygen-derived free radical scavenger, and a cholecystokinin type 1 (CCK1) receptor inhibitor for inhibiting [125I]BH-CCK-8S with IC50 of 37.7 μM.
Synonyms: OPC12759; Proamipide
4.5
*For Research Use Only !
Change View
| Size | Price | VIP Price |
DE Stock US Stock |
Asia Stock Global Stock |
In Stock |
| {[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.p_spot_brand_remark ]} 1-2 weeks {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock Inquiry - | Login - + |
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ item.p_spot_brand_remark ]}
1-2weeks
Inquiry
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
Asia Stock: Ship in 3-5 business days
EU Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Faisal Aziz ; Kanamata Reddy ; Virneliz Fernandez Vega ; Raja Dey ; Katherine A. Hicks ; Sumitha Rao , et al.
Abstract: The suppressor of T cell receptor signaling (Sts) proteins are negative regulators of immune signaling. Genetic inactivation of these proteins leads to significant resistance to infection. From a 590,000 compound high-throughput screen, we identified the 2-(1H)-quinolinone derivative, rebamipide, as a putative inhibitor of Sts phosphatase activity. Rebamipide, and a small library of derivatives, are competitive, selective inhibitors of Sts-1 with IC50 values from low to submicromolar. SAR analysis indicates that the quinolinone, the acid, and the amide moieties are all essential for activity. A crystal structure confirmed the SAR and reveals key interactions between this class of compound and the protein. Although rebamipide has poor cell permeability, we demonstrated that a liposomal preparation can inactivate the phosphatase activity of Sts-1 in cells. These studies demonstrate that Sts-1 enzyme activity can be pharmacologically inactivated and provide foundational tools and insights for the development of immune-enhancing therapies that target the Sts proteins.
Show More >
Purchased from AmBeed: 2251-65-2 ; 90098-04-7 ; 4876-14-6 ; 90098-08-1 ; 874-60-2 ; 4876-10-2 ; 7158-32-9 ; 5271-67-0 ; 118-45-6 ; 73-22-3 ; 56-41-7 ; 34893-92-0 ; 403-43-0 ; 58757-38-3 ; 76903-88-3 ; 52-90-4 ; 6068-72-0 ; 4122-68-3 ; 2243-83-6 ; 38818-50-7 ; 16331-45-6 ; 36823-88-8 ; 90098-06-9 ; 90098-05-8 ; 3024-72-4 ; 618-46-2 ; 63024-43-1 ; 22980-09-2 ; 681806-75-7 ; 39544-74-6
Show More >
| CAS No. : | 90098-04-7 |
| Formula : | C19H15ClN2O4 |
| M.W : | 370.79 |
| SMILES Code : | O=C(O)C(NC(C1=CC=C(Cl)C=C1)=O)CC2=CC(NC3=C2C=CC=C3)=O |
| Synonyms : |
OPC12759; Proamipide
|
| MDL No. : | MFCD00866895 |
| InChI Key : | ALLWOAVDORUJLA-UHFFFAOYSA-N |
| Pubchem ID : | 5042 |
| GHS Pictogram: |
|
| Signal Word: | Danger |
| Hazard Statements: | H301 |
| Precautionary Statements: | P264-P270-P301+P310+P330-P405-P501 |
| Class: | 6.1 |
| UN#: | 2811 |
| Packing Group: | Ⅲ |
In Vitro:
|
Cell Line
|
Concentration | Treated Time | Description | References |
| Rat intestinal epithelial (RIE) cells | 2 mM | 12 hours | To evaluate the effect of rebamipide on RIE cell migration, results showed that rebamipide significantly promoted RIE cell migration and wound healing. | World J Gastroenterol. 2011 Sep 7;17(33):3802-9. |
| Jurkat cells | 50, 75, 100 or 200 µM | 20 minutes | To determine the effect of rebamipide on Sts-1 dephosphorylation of Zap-70, results showed that rebamipide effectively inhibited Sts-1 activity when delivered via liposomes | J Med Chem. 2024 Feb 8;67(3):1949-1960. |
| MKN-1 gastric cancer cells | 5 mM | 24 hours | Rebamipide significantly suppressed the expression of both PLD1 and PLD2 mRNA levels | Exp Mol Med. 2010 Aug 31;42(8):555-64. |
| CD19+B cells | 300 µM | 72 hours | To investigate the effects of rebamipide on B cell development, results showed that rebamipide significantly decreased the proportion of FAS+GL-7+GC B cells and inhibited the production of total IgG and IgG1 | Clin Exp Immunol. 2014 Oct;178(1):9-19. |
In Vivo:
|
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
| Wistar rats | TNBS-induced colitis model | Intrarectal administration | 1% rebamipide | Twice daily, starting from day 7 to day 14 | To evaluate the therapeutic effect of rebamipide on TNBS-induced colitis, results showed that rebamipide significantly promoted the healing of colonic ulcers and reduced inflammatory responses. | World J Gastroenterol. 2011 Sep 7;17(33):3802-9. |
| Rabbits | Dry eye model | Eyelid application | 1.5% REB formulations (0.3 g) | Once a day (14:00) for six days | To evaluate the therapeutic effect of REB-NPs on dry eye. Results showed that REB-NPs increased lacrimal fluid volume and mucin levels, improved tear film breakup time, and stabilized the ocular surface. | Pharmaceutics. 2020 Feb 14;12(2):155 |
| Rats | Acetic acid-induced colitis model | Oral gavage | 100 mg/kg | Once daily for seven days | Rebamipide significantly improved the colonic injury by lowering the colonic disease activity index and macroscopic mucosal injury score. Moreover, it mitigated the histopathological aberrations and microscopical damage score. The favorable outcomes of rebamipide were driven by combating inflammation evidenced by dampening the colonic expression of NF-κBp65 and the pro-inflammatory markers CRP, TNF-α, and IL-6. In the same context, rebamipide curtailed the colonic pro-inflammatory PI3K/AKT pathway as seen by downregulating the immunostaining of PI3K and p-AKT(Ser473) signals. | Pharmaceuticals (Basel). 2023 Apr 2;16(4):533 |
| Kunming mice | Diclofenac-induced small intestinal permeability model | Intragastric | 100 mg/kg, 200 mg/kg, 400 mg/kg | Once daily for 3 days | To investigate the protective effect and mechanism of rebamipide on diclofenac-induced small intestinal permeability. Results showed that rebamipide significantly reduced Evans Blue and FITC-D permeation, improved inter-cellular tight junctions, decreased intestinal MDA content and MPO activity, and enhanced mitochondrial function. | World J Gastroenterol. 2012 Mar 14;18(10):1059-66 |
| Beagles | Repeated dose toxicity tests | Oral | 150 mg/kg | 4 weeks | Determination of the no observed adverse event level (NOAEL) | Pharmaceuticals (Basel). 2023 Jan 16;16(1):132 |
| Mice | Repeated dose toxicity tests | Oral | 167 mg/kg | 4 weeks | Determination of the no observed adverse event level (NOAEL) | Pharmaceuticals (Basel). 2023 Jan 16;16(1):132 |
| BALB/c mice | Environmental dry eye stress model (EDES) | Topical application | 2% | Four times daily for four days (applied at 9:00 am, 12:00 pm, 3:00 pm, and 6:00 pm); then twice daily, before and after exposure to EDES for three days | This study aimed to compare the effects of 2% rebamipide eye drops with 0.1% sodium hyaluronate (HA) eye drops on tear function, ocular surface abnormalities, corneal sensation, and subbasal corneal nerves in male BALB/c mice after exposure to EDES by IVCM. Results showed that the lissamine green staining score was significantly lower, corneal sensitivity was more preserved, subbasal nerve fiber density was significantly higher, and DC density was significantly lower in the 2% rebamipide group compared to the HA group. | Int J Mol Sci. 2019 Aug 18;20(16):4031 |
| C57BL/6 mice | Dry eye model | Eye drops | 2% | Four times daily for 2 weeks | To evaluate the therapeutic effects of 2% rebamipide on dry eye mice, the results showed that rebamipide significantly reduced corneal staining scores, increased tear film breakup time and tear production, restored histological changes in the cornea, conjunctiva and lacrimal gland, and downregulated pro-inflammatory cytokines while upregulating anti-inflammatory cytokines. | Mol Med Rep. 2019 May;19(5):4011-4018 |
| Japanese white rabbits | BAC-induced lacrimal duct damage model | Lacrimal duct injection | 2% | Once daily for 3 consecutive days | To investigate the protective effect of rebamipide on BAC-induced damage to LDECs. Results showed that rebamipide significantly reduced BAC-induced tissue disruption and neutrophil infiltration, and preserved tight junction protein expression. | Sci Rep. 2020 Feb 3;10(1):1641 |
| SKG mice | Zymosan-induced arthritis model | Intraperitoneal injection | 6 mg/kg | Three times per week for 11 weeks | To investigate the effect of rebamipide on arthritis severity, results showed that rebamipide attenuated the severity of clinical and histological arthritis, reduced the number of Th1, Th2, Th17 cells, and increased the number of Treg cells | Clin Exp Immunol. 2014 Oct;178(1):9-19. |
| SKG ZAP-70W163C mice | Curdlan-induced spondyloarthritis model | Intraperitoneal injection | 6 mg/kg | 3 times a week for 14 weeks | Rebamipide prevented peripheral arthritis and intestinal inflammation by regulating Th17/Treg cell imbalance, reduced clinical and histological scores, and decreased IL-17 and TNF-α expression | J Transl Med. 2016 Jun 27;14(1):190 |
Clinical Trial:
| NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
| NCT00996788 | Dyspepsia|Chronic Gastritis | PHASE3 | COMPLETED | 2025-01-12 | Division of Gastroenterology D... More >>epartment of Internal Medicine - Cipto Mangunkusumo Hospital, Faculty of Medicine University of Indonesia, Jakarta, Indonesia Less << |
| NCT00201955 | Keratoconjunctivitis Sicca | PHASE3 | COMPLETED | 2025-07-06 | Harold Helms, MD, Birmingham, ... More >>Alabama, 35205, United States|Michael Bernstein, MD, Birmingham, Alabama, 35216, United States|I Care! Eye Care!, Flagstaff, Arizona, 860001, United States|Harvey and Bernice Jones Eye Institute, Little Rock, Arkansas, 72205, United States|United Medical Research Institute, Inglewood, California, 90301, United States|Benchmark Research, San Francisco, California, 94102, United States|Southern California Clinical Research, Inc., San Marino, California, 91108, United States|Colorado Eye Associates, PC, Colorado Springs, Colorado, 80907, United States|Danbury Eye Physicians and Surgeons, P.C., Danbury, Connecticut, 06810-4005, United States|Florida Ophthalmic Institute, Gainesville, Florida, 32605-3192, United States|Florida Wellcare Alliance, L.C., Inverness, Florida, 34452, United States|Shettle Eye Center, Largo, Florida, 33770, United States|Suncoast Clinical Research, Inc., New Port Richey, Florida, 34652, United States|Tukio Institute for Clinical Research, North Miami Beach, Florida, 33169, United States|Magnolia Research Group, Inc., Ocala, Florida, 34471, United States|Radiant Research - West Palm Beach, West Palm Beach, Florida, 33407, United States|Vision Incorporated, Savannah, Georgia, 31406, United States|Welborn Clinic, Evansville, Indiana, 47714, United States|Heartland Research Associates, LLC, Wichita, Kansas, 67207, United States|Wichita Clinic, PA, Wichita, Kansas, 67208, United States|Taustine Eye Center, Louisville, Kentucky, 40217, United States|Bossier Optical, Inc., Bossier, Louisiana, 71111, United States|Stevenson Medical Surgical Eye Center, New Orleans, Louisiana, 70119, United States|Family Eye Centers, New Orleans, Louisiana, 70127, United States|Ophthalmic Research Associates, Inc., N. Andover, Massachusetts, 01845, United States|Minnesota Eye Associates, Minneapolis, Minnesota, 55404, United States|Depremont Eye Specialists, Gulfport, Mississippi, 39507, United States|Opthalmology Associates, Creve Coeur, Missouri, 63141, United States|Clinical Research Laboratories, Piscataway, New Jersey, 08854, United States|Ophthalmology Associates, Princeton, New Jersey, 08540, United States|Eye Care Associates, Bethpage, New York, 11021, United States|Ophthmalmic Consultants of Long Island, Lynbrook, New York, 11563, United States|Mt. Sinai Medical Center School of Medicine, New York, New York, 10029, United States|Rochester Ophthalmological Group, Rochester, New York, 14618, United States|Ophthalmic Consultants of Long Island, Rockville Center, New York, 11570, United States|Ophthalmic Consultants of Long Island, Valley Stream, New York, 11581, United States|Western Wake Eye Center, P.A., Cary, North Carolina, 27511, United States|Southeast Clinical Research Associates, Charlotte, North Carolina, 28210, United States|Horizon Eye Care - Clinical Research Dept., Charlotte, North Carolina, 28211, United States|Cornerstone Research Care, High Point, North Carolina, 27262, United States|Carolina Eye Associates, Southern Pines, North Carolina, 28387, United States|Cincinnati Eye Institute, Cincinnati, Ohio, 45242, United States|Comprehensive Opthalmology & Optical Services, Cleveland, Ohio, 44115, United States|Bend Medical Clinic, Bend, Oregon, 97701, United States|Medical Eye Center, Medford, Oregon, 97504, United States|Valley Clinical Research Center, Easton, Pennsylvania, 18045, United States|Philadelphia Eye Associates, Philadelphia, Pennsylvania, 19148, United States|Glaucome-Cataract Consultants, Pittsburgh, Pennsylvania, 15243, United States|University of Pittsburg Eye and Ear Institute, Pittsburg, Pennsylvania, 15233, United States|Black Hills Regional Eye Institute, Rapid City, South Dakota, 57701, United States|Total Eye Care, P.A., Memphis, Tennessee, 38119, United States|Corona Research Consultants, Inc., El Paso, Texas, 79904, United States|The University of Texas Medical Branch, Galveston, Texas, 77555, United States|Physician Research Network, Houston, Texas, 77002, United States|Houston, Texas, 77002, United States|Medical Center Ophthalmology, Houston, Texas, 77030, United States|Houston Eye Associates, Houston, Texas, 77125, United States|Sun Research Institute, San Antonio, Texas, 78205, United States|Eye Clinic of South Texas, San Antonio, Texas, 78209, United States|Advanced Healthcare Clinical Research Center, Milwaukee, Wisconsin, 21209, United States Less << |
| NCT01759108 | Improving Symptoms of Dry Mout... More >>h in Sj?gren's Syndrome Less << | UNKNOWN | 2025-09-21 | Faculty of Medicine, Universit... More >>y of Alexandria, Alexandria, 203, Egypt Less << | |
| NCT00201981 | Keratoconjunctivitis Sicca | PHASE3 | COMPLETED | 2025-02-07 | Alabama Research Center, LLC, ... More >>Birmingham, Alabama, 35209, United States|Sun Valley Arthritis Center, Ltd., Glendale, Arizona, 85308, United States|Pivotel Research Center, Peoria, Arizona, 85381, United States|Hope research Institute, Phoenix, Arizona, 85006, United States|Buena Vista Eye Care Center, Phoenix, Arizona, 85012, United States|Radiant Research, Scottsdale, Arizona, 85251, United States|Sall Eye Research Center, Artesia, California, 90701-5653, United States|Radiant Research - Irvine, Irvine, California, 92618, United States|Scripps Clinic Medical Group, Inc., La Jolla, California, 92037, United States|American Eye Institute, Los Angeles, California, 90048, United States|Eye Clinic of San Diego, San Diego, California, 92103, United States|Healthcare Partners Medical Group, Torrance, California, 90503, United States|Centennial Eye Associates, Centennial, Colorado, 80112, United States|Corneal Consultants of Colorado, Littleton, Colorado, 80120, United States|Western States Clinical Research, Inc., Wheat Ridge, Colorado, 80033, United States|Peter C. Donshik, MDPC, Bloomfield, Connecticut, 06002, United States|Opticare Eye Health Center, Waterbury, Connecticut, 06708, United States|The Eye Associates, Bradenton, Florida, 34209, United States|Hernando Eye Institute, Brooksville, Florida, 34613, United States|Radiant Research, Inc. - Lake Worth, Lake Worth, Florida, 33461, United States|Suncoast Clinical Research, Inc., New Port Richey, Florida, 34652, United States|Eye Associates International, Ormond Beach, Florida, 32174, United States|Pinellas Eye Center, Pinellas Park, Florida, 33781, United States|Ft. Lauderdale Eye Institute, Sunrise, Florida, 33351, United States|Marvin E. Greenberg, MD PA 7, Tamarac, Florida, 33321, United States|Clinical Research of West Florida, Inc., Tampa, Florida, 33603, United States|International Eye Center, Tampa, Florida, 33603, United States|Omni Eye Services, Atlanta, Georgia, 30342, United States|University of Kentucky, Department of Ophthamology, Lexington, Kentucky, 40536-0293, United States|Kentucky Lions Eye Center, Louisville, Kentucky, 40222, United States|Gulf Coast Research Associates, Inc., Baton Rouge, Louisiana, 70808, United States|Danial Long, MD, Gretna, Louisiana, 70056, United States|Lakeview Optical, New Orleans, Louisiana, 70124, United States|Eye Center Northeast, Bangor, Maine, 04401, United States|Krieger Eye Institute, Baltimore, Maryland, 21215, United States|The Wilmer Eye Institute, Lutherville, Maryland, 21093, United States|New England Eye Center, Boston, Massachusetts, 02111, United States|The Eye Institute - Lahey Clinic North, Peabody, Massachusetts, 01960, United States|Mississippi Eye Associates, Ocean Springs, Mississippi, 39564, United States|Montana Medical Research, LLC, Missoula, Montana, 59804, United States|Clinical Research Center of Nevada, Las Vegas, Nevada, 89104, United States|Eye Associates of New Mexico, Albuquerque, New Mexico, 87109, United States|Western New York Eye Center, Orchard Park, New York, 14127, United States|Glaucoma Consultants of the Capital Region, Slingerlands, New York, 12159, United States|Orellana Retina Associates, PLLC, Raleigh, North Carolina, 27612, United States|University Hospitals of Cleveland, Cleveland, Ohio, 44106-5068, United States|Comprehensive Opthalmology & Optical Services, Cleveland, Ohio, 44115, United States|Clinical Research Source, Inc., Perryberg, Ohio, 43551, United States|Clinical Research Institute of Southern Oregon, Medford, Oregon, 97504, United States|Northwest Corneal Services, Portland, Oregon, 97223, United States|Vision Surgery and Laser Center, Roseburg, Oregon, 97470, United States|West Hills Vision Center, Moon Township, Pennsylvania, 15108, United States|Glaucoma Consultants and Center for Eye Research, Mt. Pleasant, South Carolina, 29464, United States|University Eye Surgeons, Maryville, Tennessee, 37803, United States|St. Luke's Eye Institute, Amarillo, Texas, 79106, United States|Eye Clinic of Austin, Austin, Texas, 78731, United States|Baylor College of Medicine, Houston, Texas, 77030, United States|Surgical Eye Associates, PA, Houston, Texas, 77055, United States|Brazosport Eye Institute, Lake Jackson, Texas, 77566, United States|Axia Research, Salt Lake City, Utah, 84107, United States|John Moran Eye Center, University of Utah, Salt Lake City, Utah, 84132, United States|Physicians Research Options, LC, Sandy, Utah, 84070, United States|Access Eye Research Center, Fredericksburg, Virginia, 22405, United States Less << |
| NCT00233363 | Xerostomia|Sjogren's Syndrome | PHASE2 | COMPLETED | 2006-01-27 | Otsuka Pharmaceutical Co., Ltd... More >>., Tokyo, Japan Less << |
| NCT00862628 | NSAIDs-induced Small-intestina... More >>l Injuries Less << | UNKNOWN | 2025-10-10 | Department of Gastroenterology... More >>, Nagoya University Graduate School of Medicine, Nagoya, Aichi Prefecture, 466-8550, Japan|Department of Gastroenterology, Nagoya University Graduate School of Medicine, Nagoya, Aichi Prefecture, 466-8550, Japan Less << | |
| NCT00233389 | Stomach Ulcer | PHASE4 | COMPLETED | 2005-09-09 | Otsuka Pharmaceutical Co., Ltd... More >>., Tokyo, Japan Less << |
| NCT04550858 | H.Pylori Infection | UNKNOWN | 2021-09-21 | - |
Tags: Rebamipide | OPC12759 | Proamipide | OPC 12759 | OPC-12759 | COX | Cyclooxygenase | gastric cancer | PGE2 | COX-2 | mucosal protection | gastroduodenal ulcer | gastritis | 90098-04-7
Precautionary Statements-General | |
| Code | Phrase |
| P101 | If medical advice is needed,have product container or label at hand. |
| P102 | Keep out of reach of children. |
| P103 | Read label before use |
Prevention | |
| Code | Phrase |
| P201 | Obtain special instructions before use. |
| P202 | Do not handle until all safety precautions have been read and understood. |
| P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
| P211 | Do not spray on an open flame or other ignition source. |
| P220 | Keep/Store away from clothing/combustible materials. |
| P221 | Take any precaution to avoid mixing with combustibles |
| P222 | Do not allow contact with air. |
| P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
| P230 | Keep wetted |
| P231 | Handle under inert gas. |
| P232 | Protect from moisture. |
| P233 | Keep container tightly closed. |
| P234 | Keep only in original container. |
| P235 | Keep cool |
| P240 | Ground/bond container and receiving equipment. |
| P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
| P242 | Use only non-sparking tools. |
| P243 | Take precautionary measures against static discharge. |
| P244 | Keep reduction valves free from grease and oil. |
| P250 | Do not subject to grinding/shock/friction. |
| P251 | Pressurized container: Do not pierce or burn, even after use. |
| P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
| P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
| P262 | Do not get in eyes, on skin, or on clothing. |
| P263 | Avoid contact during pregnancy/while nursing. |
| P264 | Wash hands thoroughly after handling. |
| P265 | Wash skin thouroughly after handling. |
| P270 | Do not eat, drink or smoke when using this product. |
| P271 | Use only outdoors or in a well-ventilated area. |
| P272 | Contaminated work clothing should not be allowed out of the workplace. |
| P273 | Avoid release to the environment. |
| P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
| P281 | Use personal protective equipment as required. |
| P282 | Wear cold insulating gloves/face shield/eye protection. |
| P283 | Wear fire/flame resistant/retardant clothing. |
| P284 | Wear respiratory protection. |
| P285 | In case of inadequate ventilation wear respiratory protection. |
| P231 + P232 | Handle under inert gas. Protect from moisture. |
| P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
| Code | Phrase |
| P301 | IF SWALLOWED: |
| P304 | IF INHALED: |
| P305 | IF IN EYES: |
| P306 | IF ON CLOTHING: |
| P307 | IF exposed: |
| P308 | IF exposed or concerned: |
| P309 | IF exposed or if you feel unwell: |
| P310 | Immediately call a POISON CENTER or doctor/physician. |
| P311 | Call a POISON CENTER or doctor/physician. |
| P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
| P313 | Get medical advice/attention. |
| P314 | Get medical advice/attention if you feel unwell. |
| P315 | Get immediate medical advice/attention. |
| P320 | |
| P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
| P321 | |
| P322 | |
| P330 | Rinse mouth. |
| P331 | Do NOT induce vomiting. |
| P332 | IF SKIN irritation occurs: |
| P333 | If skin irritation or rash occurs: |
| P334 | Immerse in cool water/wrap n wet bandages. |
| P335 | Brush off loose particles from skin. |
| P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
| P337 | If eye irritation persists: |
| P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
| P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P342 | If experiencing respiratory symptoms: |
| P350 | Gently wash with plenty of soap and water. |
| P351 | Rinse cautiously with water for several minutes. |
| P352 | Wash with plenty of soap and water. |
| P353 | Rinse skin with water/shower. |
| P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
| P361 | Remove/Take off immediately all contaminated clothing. |
| P362 | Take off contaminated clothing and wash before reuse. |
| P363 | Wash contaminated clothing before reuse. |
| P370 | In case of fire: |
| P371 | In case of major fire and large quantities: |
| P372 | Explosion risk in case of fire. |
| P373 | DO NOT fight fire when fire reaches explosives. |
| P374 | Fight fire with normal precautions from a reasonable distance. |
| P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
| P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
| P378 | |
| P380 | Evacuate area. |
| P381 | Eliminate all ignition sources if safe to do so. |
| P390 | Absorb spillage to prevent material damage. |
| P391 | Collect spillage. Hazardous to the aquatic environment |
| P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
| P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
| P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
| P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
| P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
| P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
| P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
| P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
| P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
| P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
| P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
| P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
| P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
| P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
| P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
| P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
| P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
| P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
| P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
| P370 + P376 | In case of fire: Stop leak if safe to Do so. |
| P370 + P378 | In case of fire: |
| P370 + P380 | In case of fire: Evacuate area. |
| P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
| P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
| Code | Phrase |
| P401 | |
| P402 | Store in a dry place. |
| P403 | Store in a well-ventilated place. |
| P404 | Store in a closed container. |
| P405 | Store locked up. |
| P406 | Store in corrosive resistant/ container with a resistant inner liner. |
| P407 | Maintain air gap between stacks/pallets. |
| P410 | Protect from sunlight. |
| P411 | |
| P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
| P413 | |
| P420 | Store away from other materials. |
| P422 | |
| P402 + P404 | Store in a dry place. Store in a closed container. |
| P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
| P403 + P235 | Store in a well-ventilated place. Keep cool. |
| P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
| P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
| P411 + P235 | Keep cool. |
Disposal | |
| Code | Phrase |
| P501 | Dispose of contents/container to ... |
| P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
| Code | Phrase |
| H200 | Unstable explosive |
| H201 | Explosive; mass explosion hazard |
| H202 | Explosive; severe projection hazard |
| H203 | Explosive; fire, blast or projection hazard |
| H204 | Fire or projection hazard |
| H205 | May mass explode in fire |
| H220 | Extremely flammable gas |
| H221 | Flammable gas |
| H222 | Extremely flammable aerosol |
| H223 | Flammable aerosol |
| H224 | Extremely flammable liquid and vapour |
| H225 | Highly flammable liquid and vapour |
| H226 | Flammable liquid and vapour |
| H227 | Combustible liquid |
| H228 | Flammable solid |
| H229 | Pressurized container: may burst if heated |
| H230 | May react explosively even in the absence of air |
| H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
| H240 | Heating may cause an explosion |
| H241 | Heating may cause a fire or explosion |
| H242 | Heating may cause a fire |
| H250 | Catches fire spontaneously if exposed to air |
| H251 | Self-heating; may catch fire |
| H252 | Self-heating in large quantities; may catch fire |
| H260 | In contact with water releases flammable gases which may ignite spontaneously |
| H261 | In contact with water releases flammable gas |
| H270 | May cause or intensify fire; oxidizer |
| H271 | May cause fire or explosion; strong oxidizer |
| H272 | May intensify fire; oxidizer |
| H280 | Contains gas under pressure; may explode if heated |
| H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
| H290 | May be corrosive to metals |
Health hazards | |
| Code | Phrase |
| H300 | Fatal if swallowed |
| H301 | Toxic if swallowed |
| H302 | Harmful if swallowed |
| H303 | May be harmful if swallowed |
| H304 | May be fatal if swallowed and enters airways |
| H305 | May be harmful if swallowed and enters airways |
| H310 | Fatal in contact with skin |
| H311 | Toxic in contact with skin |
| H312 | Harmful in contact with skin |
| H313 | May be harmful in contact with skin |
| H314 | Causes severe skin burns and eye damage |
| H315 | Causes skin irritation |
| H316 | Causes mild skin irritation |
| H317 | May cause an allergic skin reaction |
| H318 | Causes serious eye damage |
| H319 | Causes serious eye irritation |
| H320 | Causes eye irritation |
| H330 | Fatal if inhaled |
| H331 | Toxic if inhaled |
| H332 | Harmful if inhaled |
| H333 | May be harmful if inhaled |
| H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
| H335 | May cause respiratory irritation |
| H336 | May cause drowsiness or dizziness |
| H340 | May cause genetic defects |
| H341 | Suspected of causing genetic defects |
| H350 | May cause cancer |
| H351 | Suspected of causing cancer |
| H360 | May damage fertility or the unborn child |
| H361 | Suspected of damaging fertility or the unborn child |
| H361d | Suspected of damaging the unborn child |
| H362 | May cause harm to breast-fed children |
| H370 | Causes damage to organs |
| H371 | May cause damage to organs |
| H372 | Causes damage to organs through prolonged or repeated exposure |
| H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
| Code | Phrase |
| H400 | Very toxic to aquatic life |
| H401 | Toxic to aquatic life |
| H402 | Harmful to aquatic life |
| H410 | Very toxic to aquatic life with long-lasting effects |
| H411 | Toxic to aquatic life with long-lasting effects |
| H412 | Harmful to aquatic life with long-lasting effects |
| H413 | May cause long-lasting harmful effects to aquatic life |
| H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL


